These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1221 related articles for article (PubMed ID: 6607324)

  • 1. Parameters of interferon action: II. Immunological effects of recombinant leukocyte interferon (IFN-alpha 2) in phase I-II trials.
    Ernstoff MS; Fusi S; Kirkwood JM
    J Biol Response Mod; 1983; 2(6):540-7. PubMed ID: 6607324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parameters of interferon action: I. Immunological effects of whole cell leukocyte interferon (IFN-alpha) in phase I-II trials.
    Ernstoff MS; Fusi S; Kirkwood JM
    J Biol Response Mod; 1983; 2(6):528-39. PubMed ID: 6363630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic administration of human leukocyte interferon to melanoma patients. III. Increased helper:suppressor cell ratios in melanoma patients during interferon treatment.
    Karavodin LM; Golub SH
    Nat Immun Cell Growth Regul; 1983-1984; 3(4):193-202. PubMed ID: 6241293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunological effects of recombinant interferon-alpha 2 in cancer patients.
    Hengst JC; Kempf RA; Kan-Mitchell J; Pham AT; Grunberg SM; Kortes VL; Mitchell MS
    J Biol Response Mod; 1983; 2(6):516-27. PubMed ID: 6663321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunomodulation by recombinant interferon-alpha 2 in a phase I trial in patients with lymphoproliferative malignancies.
    Ozer H; Gavigan M; O'Malley J; Thompson D; Dadey B; Nussbaum-Blumenson A; Snider C; Rudnick S; Ferraresi R; Norred S
    J Biol Response Mod; 1983; 2(6):499-515. PubMed ID: 6607323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative study on the effects of recombinant alpha-2 interferon on immune function in patients with disseminated melanoma.
    Hersey P; Coates A; Rallings M; Hall C; MacDonald M; Spurling A; Edwards A; McCarthy WH; Milton GW
    J Biol Response Mod; 1986 Jun; 5(3):236-49. PubMed ID: 3487622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of natural killer cell cytotoxicity in the peripheral blood of patients receiving interferon therapy.
    Spina CA; Fahey JL; Durkos-Smith D; Dorey F; Sarna G
    J Biol Response Mod; 1983; 2(5):458-69. PubMed ID: 6644350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of natural killer cell cytotoxicity of cancer patients treated with recombinant interferon.
    Lotzová E; Savary CA; Quesada JR; Gutterman JU; Hersh EM
    J Natl Cancer Inst; 1983 Nov; 71(5):903-10. PubMed ID: 6580490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of natural killing activity by lymphoblastoid interferon in cancer patients.
    Koren HS; Brandt CP; Tso CY; Laszlo J
    J Biol Response Mod; 1983; 2(2):151-65. PubMed ID: 6644332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of human natural killer cell cytotoxicity by recombinant leukocyte interferon clone A.
    Lotzová E; Savary CA; Gutterman JU; Quesada JR; Hersh EM
    J Biol Response Mod; 1983; 2(5):482-96. PubMed ID: 6644351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunologic monitoring studies in advanced cancer patients treated with recombinant human gamma interferon (IFN-gamma 4A).
    Romano PJ; Lipton A; Harvey HA; Bartholomew MJ; Giudice G; Kloszewski F; Witkowski L; Downing MR
    Mol Biother; 1989; 1(4):208-12. PubMed ID: 2510768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic administration of human leukocyte interferon to melanoma patients. I. Effects on natural killer function and cell population.
    Golub SH; Dorey F; Hara D; Morton DL; Burk MW
    J Natl Cancer Inst; 1982 May; 68(5):703-10. PubMed ID: 6175787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I evaluation of a synthetic mutant of beta-interferon.
    Hawkins M; Horning S; Konrad M; Anderson S; Sielaff K; Rosno S; Schiesel J; Davis T; DeMets D; Merigan T
    Cancer Res; 1985 Nov; 45(11 Pt 2):5914-20. PubMed ID: 4053062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Multidisciplinary therapy using interferon and immunological evaluation for glioma patients: two-color analysis of T cell subsets].
    Numa Y; Kawamoto K; Matsumura H
    No Shinkei Geka; 1991 Feb; 19(2):121-8. PubMed ID: 1708857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative in vivo and in vitro activation of human natural killer cells by two recombinant alpha-interferons differing in antiviral activity.
    Edwards BS; Hawkins MJ; Borden EC
    Cancer Res; 1984 Jul; 44(7):3135-9. PubMed ID: 6586292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of recombinant interleukin-2 and cyclophosphamide: augmentation of cellular immunity and T-cell mitogenic response with long-term administration of rIL-2.
    Kolitz JE; Wong GY; Welte K; Merluzzi VJ; Engert A; Bialas T; Polivka A; Bradley EC; Konrad M; Gnecco C
    J Biol Response Mod; 1988 Oct; 7(5):457-72. PubMed ID: 3263471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo priming effects of interferon-beta ser on NK activity of peripheral blood mononuclear cells in cancer patients.
    Fujimiya Y; Wagner RJ; Groveman S; Sielaff K; Kohsaka T; Nakayama M
    Ther Immunol; 1995 Feb; 2(1):15-22. PubMed ID: 7553067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effects of nephrectomy and interferon administration on immunological parameters in patients with renal cell carcinoma].
    Arima K; Yanagawa M; Sugimura Y; Tochigi H; Kawamura J; Saitoh K; Yamazaki Y; Mori O; Oomoto Y; Nakagawa M
    Hinyokika Kiyo; 1994 Jun; 40(6):469-74. PubMed ID: 8073952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intraperitoneal administration of human recombinant interferon-alpha in patients with ovarian cancer: effects on lymphocyte phenotype and cytotoxicity.
    Lichtenstein A; Spina C; Berek JS; Jung T; Zighelboim J
    Cancer Res; 1988 Oct; 48(20):5853-9. PubMed ID: 3167841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 62.